VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, HC Wainwright dropped their price objective on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $3.17.

VolitionRx Stock Up 2.7%

Shares of VNRX stock traded up $0.01 during mid-day trading on Wednesday, hitting $0.31. 1,069,759 shares of the company’s stock were exchanged, compared to its average volume of 468,340. The stock has a market cap of $37.70 million, a price-to-earnings ratio of -0.85 and a beta of 1.24. The stock has a 50-day simple moving average of $0.48 and a two-hundred day simple moving average of $0.59. VolitionRx has a fifty-two week low of $0.29 and a fifty-two week high of $0.94.

Insider Activity

In other news, Director Guy Archibald Innes bought 96,153 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The stock was acquired at an average price of $0.51 per share, for a total transaction of $49,038.03. Following the acquisition, the director owned 1,062,967 shares of the company’s stock, valued at $542,113.17. This trade represents a 9.95% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Cameron John Reynolds purchased 110,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 14th. The stock was acquired at an average price of $0.51 per share, for a total transaction of $56,100.00. Following the acquisition, the chief executive officer directly owned 2,534,847 shares of the company’s stock, valued at $1,292,771.97. This trade represents a 4.54% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 289,229 shares of company stock valued at $146,557 over the last 90 days. 10.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On VolitionRx

Several large investors have recently made changes to their positions in VNRX. Virtu Financial LLC purchased a new position in shares of VolitionRx in the 3rd quarter valued at $28,000. Blair William & Co. IL purchased a new stake in VolitionRx during the 2nd quarter worth $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRx in the 2nd quarter valued at $52,000. Silverberg Bernstein Capital Management LLC raised its position in VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after purchasing an additional 60,209 shares during the period. Finally, Citadel Advisors LLC lifted its stake in shares of VolitionRx by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after purchasing an additional 135,775 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.